Status:
COMPLETED
Botulinum Toxin Type A and Modified Constraint-Induced Movement Therapy for Poststroke Upper Extremity Spasticity
Lead Sponsor:
Kaohsiung Veterans General Hospital.
Conditions:
Stroke
Eligibility:
All Genders
45-75 years
Phase:
NA
Brief Summary
Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT) are both promising approaches to enhance recovery after stroke. However, the combined application of th...
Detailed Description
Botulinum toxin type A (BtxA) injection and modified constraint-induced movement therapy (mCIMT)are both promising approaches to enhance recovery after stroke. However, the combined application of the...
Eligibility Criteria
Inclusion
- age 18 to 80 years
- at least 1 year after a unilateral stroke
- modified ashworth scale (MAS) score \> 3 in the elbow, wrist or finger flexors
- ability to actively extend \> 10 degrees at metacarpophalangeal and interphalangeal joints and 20 degrees at wrist of the affected upper limb (minimal motor criteria).
Exclusion
- presence of fixed joint contractures
- serious balance problems
- preexisting neurological deficits, neuromuscular diseases or uncontrolled medical conditions
- significant cognitive deficits (Mini-Mental Status Examination score \< 24)
- excessive pain in the affected upper limb
- previous treatment with Botulinum toxin A, neurolytic agents or surgery for spasticity
- All patients were not currently participating in any experimental studies and did not receive concomitant oral anti-spastic medication during the study period
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00723866
Start Date
December 1 2005
End Date
June 1 2008
Last Update
August 1 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.